Markets:

Overview

News

Currencies

International

Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

9.140 +0.320 (+3.63%)

Streaming Delayed Price Updated: 1:33 PM EDT, Aug 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

20 Stocks Moving in Thursday's Pre-Market Session ↗

January 13, 2022

Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-...

Via Benzinga

Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer ↗

January 13, 2022

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 12, 2022

Gainers Biomerica (NASDAQ:BMRA) stock inc...

Via Benzinga

Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer

January 12, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Releases Updated Corporate Presentation

January 10, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference

January 04, 2022

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting

December 10, 2021

From Puma Biotechnology, Inc.

Via Business Wire

The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares ↗

December 10, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...

Via Benzinga

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2021

From Puma Biotechnology, Inc.

Via Business Wire

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗

November 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...

Via Benzinga

Topics Intellectual Property

Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)

November 23, 2021

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial ↗

November 22, 2021

Puma Biotechnology Inc (NASDAQ: PBYI) announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH...

Via Benzinga

Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting

November 20, 2021

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS)

November 19, 2021

From Puma Biotechnology, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 05, 2021

Gainers Ontrak (NASDAQ:OTRK) shares rose 21.82% to $11.78 during Friday's pre-market session. The market value of their outstanding shares is at $225.5 million. As per...

Via Benzinga

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

64 Stocks Moving In Friday's Mid-Day Session ↗

November 05, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the...

Via Benzinga

The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗

November 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...

Via Benzinga

28 Stocks Moving in Friday's Pre-Market Session ↗

November 05, 2021

Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 65.8% to $2.14 in pre-market trading after the company announced its ReBoot device has been granted designation as a Breakthrough...

Via Benzinga

Puma Biotechnology Reports Third Quarter 2021 Financial Results

November 04, 2021

From Puma Biotechnology, Inc.

Via Business Wire

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

October 21, 2021

From Puma Biotechnology, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗

October 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

October 06, 2021

From Puma Biotechnology, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2021 ↗

September 28, 2021

Upgrades For Bouygues (OTC:BOUYF), Jefferies upgr...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 28, 2021

Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 70.28% to $9.11 during Tuesday's pre-market session. The company's market cap stands at $24.5...

Via Benzinga

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗

October 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.